Publications by authors named "Kazuya Horiuchi"

Article Synopsis
  • The EXTRA study is the first research trial to explore predictive biomarkers for the effectiveness of afatinib in patients with specific mutations in nonsmall cell lung cancer (NSCLC) using various biological analyses.
  • Conducted in Japan, the prospective study involved 103 untreated patients and measured metrics like progression-free survival (PFS) and overall survival (OS) while administering afatinib at an initial daily dose of 40 mg.
  • Results showed that after a median follow-up of 35 months, the median PFS was 18.4 months, with a 3-year PFS rate of 23.3%, and a 3-year OS rate of 58.5%, indicating a positive response to afatinib in
View Article and Find Full Text PDF

Patients with EGFR-mutated non-small cell lung cancer (NSCLC) exhibit resistance to EGFR-tyrosine kinase inhibitors (TKIs) within 9-14 months of therapy. Recently, EGFR-mutated NSCLC has demonstrated the potential for heterogeneity; therefore, the manner of clonal heterogeneity may impact the duration of progression-free and overall survival and other parameters affecting EGFR-TKI treatment efficacy. However no predictive biomarker of these favorable treatment efficacies has been identified to date.

View Article and Find Full Text PDF

Purpose: A combination therapy with inhaled corticosteroid (ICS) and a long-acting β agonist (LABA) is the standard treatment for asthmatic patients, and step-down treatment is recommended once control has been achieved. However, little data exist that evaluate the long-term outcomes after step-down treatment.

Objective: To compare the long-term outcomes of step-down therapy with ICS/LABA or ICS alone for asthmatic patients who have achieved well-controlled asthma by the ICS (250 µg fluticasone)/LABA (50 µg salmeterol) combination (SFC, two puffs per day).

View Article and Find Full Text PDF